iRhythm Technologies announced that its next generation long-term ambulatory cardiac monitor – the Zio monitor ECG System – has received CE mark certification under the European Union’s Medical Device Regulation 2017/745 from its Notified Body, the BSI Group. The Zio monitor ECG System secured its CE mark based on compliance to EU MDR standards of performance, quality, safety, and efficacy, along with the body of clinical evidence supporting Zio in detecting potential cardiac arrhythmias.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IRTC:
- iRhythm Technologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- iRhythm price target raised by $15 at Truist, here’s why
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- iRhythm just upgraded at Citi, here’s why
- Citi gets more bullish on iRhythm, upgrades shares
